Florian Krammer, PhD
img_Florian Krammer
PROFESSOR | Microbiology
PROFESSOR | Pathology, Molecular and Cell Based Medicine
Research Topics
Immunology, Infectious Disease, Influenza Virus, Mucosal Immunology, Vaccine Development, Viruses and Virology
Multi-Disciplinary Training Area
Microbiology [MIC]

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Krammer during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

  • Trudeau Institute
  • enGenes
  • Pfizer Inc., U.S. Pharmaceuticals Group

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • GSK plc.
  • Gritstone
  • Third Rock Ventures
  • Avimex
  • Castlevax

Editorial Services

  • Elsevier, journal Vaccine

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Amovir
  • Gritstone
  • Castlevax


  • Amovir
  • Castlevax

Outside Employment

  • Medical University of Vienna

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.